Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics in a significant all-cash transaction valued at approximately $2.9 billion. The deal, announced on Monday, April 6, 2026, will see Neurocrine pay $53.00 in cash for each share of Soleno common stock. This strategic acquisition is centered on obtaining Vykat XR, the sole therapy approved by the U.S. Food and Drug Administration for the treatment of hyperphagia in patients with Prader-Willi syndrome, a rare genetic disorder.
Strategic Rationale and Portfolio Expansion
For Neurocrine, the acquisition represents a major expansion of its rare disease portfolio. The company already markets two other products: Ingrezza, which generated $2.51 billion in revenue during 2025, and Crenessity, which contributed $301 million. Vykat XR will become Neurocrine's third commercial-stage asset. Neurocrine's Chief Executive Officer, Kyle Gano, characterized Vykat XR as "a potential blockbuster in the making," signaling high expectations for the drug's commercial trajectory. The company plans to focus its commercial efforts exclusively on the U.S. market for the foreseeable future, with no immediate plans to launch the therapy in Europe.
Financial Details and Market Reaction
The $53 per share offer price represents a premium of approximately 34% over Soleno's closing price on April 2, 2026, and is about 51% higher than its 30-day volume-weighted average price. Soleno's stock last traded at $52.25, just below the tender offer price. Neurocrine intends to fund the acquisition using its existing cash reserves and a modest amount of prepayable debt. The agreement includes no financing condition, indicating confidence in completing the transaction.
Analysts responded positively to the announcement. Brian Abrahams of RBC Capital Markets described the deal as providing a "third leg to the story" for Neurocrine, diversifying its revenue base. Josh Schimmer of Cantor Fitzgerald projected that Vykat XR could achieve annual sales exceeding $1 billion by 2029, highlighting its blockbuster potential.
Vykat XR: A Key Asset in Rare Disease
Vykat XR gained FDA approval on March 26, 2025, and was launched commercially on April 14, 2025. In its first partial year on the market, the drug generated $190 million in revenue. It addresses hyperphagia, a life-threatening, insatiable hunger that leads to compulsive food-seeking behavior in individuals with Prader-Willi syndrome. The companies estimate the U.S. patient population for this condition to be around 10,000. Importantly, intellectual property protection for Vykat XR is expected to extend into the mid-2040s, providing a long commercial runway.
Anish Bhatnagar, Chairman and CEO of Soleno, stated that Neurocrine is "the right strategic partner" to maximize the reach and impact of Vykat XR for the Prader-Willi syndrome community. Gano emphasized that Neurocrine's strategy is not to position Vykat XR as a general weight-loss therapy but to initiate treatment earlier in the patient journey and focus on achieving long-term weight stability for this specific population.
Transaction Timeline and Conditions
The tender offer is expected to be completed within the next 90 days, subject to customary closing conditions. These include the tender of a majority of Soleno's outstanding shares and the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The merger agreement includes a termination date of October 5, 2026, which can be extended to January 5, 2027 under certain circumstances. Should the deal not close by these dates, either party may have the right to walk away.
This acquisition underscores the continued strategic consolidation within the biotechnology sector, particularly for companies with approved, commercial-stage assets addressing high-unmet-need rare diseases. It provides Soleno shareholders with a substantial cash premium while delivering Neurocrine a near-term, revenue-generating product with significant growth potential.
